Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Int J Biochem Cell Biol. 2021 Feb;131:105901. doi: 10.1016/j.biocel.2020.105901. Epub 2020 Dec 10.
Oncogenic KRAS is one of the most common drivers of human cancer. Despite intense research, no effective therapy to directly inhibit oncogenic KRAS has yet been approved and KRAS mutant tumors remain associated with a poor prognosis. This short review discusses the current knowledge of the redox regulation of RAS and examines the newest findings on cysteine 118 (C118) as a potential novel target for KRAS inhibition.
致癌性 KRAS 是人类癌症中最常见的驱动因素之一。尽管进行了深入研究，但尚未批准任何直接抑制致癌性 KRAS 的有效疗法，并且 KRAS 突变肿瘤仍然与预后不良相关。本文简要综述了 RAS 的氧化还原调控的最新知识，并探讨了半胱氨酸 118（C118）作为 KRAS 抑制的潜在新靶点的最新发现。
